Treatment options for osteoporosis and decision making criteria: 2009

Salud Publica de Mexico

Volumn 51, Issue SUPPL.1, 2009, Pages

  Ortiz Luna, Guillermo ^a   García Hernández, Pedro ^b   Tamayo Orozco, Juan A ^a,c  

^a INSTITUTO NACIONAL DE PERINATOLOGÍA   (Mexico)

^b HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^c Comité Mexicano para la Prevención de la Osteoporosis AC ^*  (Mexico)

Author keywords

Anabolic; Benefit; Catabolic; Cost effectiveness; Diagnosis; Drugs; Mineralization; Osteoporosis management; Treatment

Indexed keywords

BONE DENSITY CONSERVATION AGENT;

ARTICLE; BONE DENSITY; BONE REMODELING; CLASSIFICATION; CLINICAL PROTOCOL; DECISION MAKING; DRUG EFFECT; FALLING; FEMALE; FRACTURE; HUMAN; MEXICO; OSTEOPOROSIS; PHYSIOLOGY;

ACCIDENTAL FALLS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CLINICAL PROTOCOLS; DECISION MAKING; FEMALE; FRACTURES, BONE; HUMANS; MEXICO; OSTEOPOROSIS;

EID: 67649088409     PISSN: 00363634     EISSN: 16067916     Source Type: Journal    
DOI: 10.1590/S0036-36342009000700015     Document Type: Article

References (87)

1. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO study group. WHO Technical Report Series. 1994;No 843.
2. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006; 17(12):1726-1733.
3. Clark P, Lavielle Pilar, Franco-Marina F, Ramirez E, Salmerón J, Kanis JA, et al. Incidente rates and life-time risk of hip fractures in Mexicans over 50 years of age: a population-based study. Osteoporosis Int 2005; 16: 2025-2030.
4. Clark P, Cons-Molina F, Deleze M, Ragi S, Haddock L, Zanchetta JR, et al. The prevalence of radiographic vertebral fractures in Latin American countries: the Latin American Vertebral Osteoporosis Study (LAVOS). Osteoporos Int 2008;19(3):269-276.
5. Morales-Torres J, Gutiérrez-Ureña S, et al. The burden of osteoporosis in Latin America. Osteoporos Int. 2004;15:625-632.
6. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761-1767.
7. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001; 12(12):989-995.
8. Cooper C, Campion G, Melton LJ. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992; 2(6):285-289.
9. Kannus P, Niemi S, Parkkari J, Palvanen M, Vuori I, Jarvinen M. Nationwide decline in incidence of hip fracture. J Bone Miner Res 2006; 21(12):1836-1838.
10. Jaglal SB, Weller I, Mamdani M, Hawker G, Kreder H, Jaakkimainen L, et al. Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong?. J Bone Miner Res 2005; 20(6):898-905.
11. KM, Nicholson GC, Watts JJ, Pasco JA, Henry MJ, Kotowicz MA, Seeman E. Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? Bone 2006;38(5):694-700
12. Siris E, Chen Y-T, Abbott T, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004; 164: 1108-1112.
13. Bonjour JP, Theintz G, Law F, Slosman D, Rizzoli R. Peak bone mass. Osteoporos Int 1994;4 Suppl 1:7-13.
14. Bonjour JP, Chevalley T. Pubertal timing, peak bone mass and fragility fracture risk. BoneKey-Osteovision. 2007; 4:30-48. Available in: http://www.bonekey-ibms.org/cgi/content/full/ibmske;4/2/30.
15. Gilsanz V, Gibbens DT, Carlson M, Boechat MI, Cann CE, Schulz EE. Peak trabecular vertebral density: a comparison of adolescent and adult females. Calcified tissue international 1988; 43(4):260-262.
16. Davis JW, Grove JS, Ross PD, Vogel JM, Wasnich RD. Relationship between bone mass and rates of bone change at appendicular measurement sites. J Bone Miner Res 1992; 7(7):719-725.
17. Buchs B, Rizzoli R, Slosman D, Nydegger V, Bonjour JP. Densité minérale osseuse de la colonne lombaire, du col et de la diaphyse fémoraux d'un échantillon de la population genevoise. Schweiz Med Wochenschr 1992; 122(30):1129-1136.
18. Melton LJ, Atkinson EJ, Khosla S, Oberg AL, Riggs BL. Evaluation of a prediction model for long-term fracture risk. J Bone Miner Res 2005; 20(4):551-556.
19. Hernandez CJ, Beaupre GS, Carter DR. A theoretical analysis of the relative influences of peak BMD, age-related bone loss and menopause on the development of osteoporosis. Osteoporos Int 2003; 14(10):843-847.
20. Black DM, Thompson DE, Bauer DC et al. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab 2000;85: 4118-4124.
21. Weycker D, Macarios D, Edelsberg J, Oster G, et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006; 17:1645-1652
22. Weycker D, Macarios D, Edelsberg J, Oster G, et al. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 2007; 18:271-277.
23. WHO scientific group on the assesment of osteoporosis at primary health care level. Geneva: World Health Organization, 2007.
24. Miller PD, Barlas S, Brenneman Sk, et al. An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med 2004; 164: 1113-1120.
25. Klibanski A. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. JAMA 2001; (6): 785-795
26. Caderette SM, Jaglal SB, Murray T, et al. Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. JAMA 2001; 286(1): 57-63.
27. Schousboe JT, Bauer DC, Nyman JA, Kane RL, Melton LJ, Ensrud KE. Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporos Int 2007;18:201-210
28. Blake GM, Fogelman I. Role of Dual-Energy X-Ray Absorptiometry in the Diagnosis and Treatment of Osteoporosis. Journal of Clinical Densitometry 2007;(10)1:102-110.
29. Arlot. Trabecular and Endocortical Bone Remodeling in Postmenopausal Osteoporosis: Comparison with Normal Postmenopausal Women. Osteoporosis Int 1990;1:41-49.
30. Meunier PJ, Boivin G. Bone mineral density reflects bone mass but also the degree of mineralisation of bone: therapeutic implications. Bone 1997;21:373-377
31. Boivin G, Meunier PJ. The degree of mineralization of bone tissue measured by computerized quantitative contact microradiography. Calcif. Tissue Int 2002;70:503-511.
32. Cameron JR, Sorenson JA. Measurement of Bone Mineral in vivo: An improved method. Science 1963;142:230-232.
33. Mazzes RB, Peppler WW, Chestnut ChD. Total body bone mineral and lean body mass by dual photon absorptiometry II. Comparison with total body calcium by neutron activation analysis. Calcif Tissue Int 1982; 3:361-363.
34. Whaner HW, Dunn WL, Brown MC. Comparison of dual energy X ray absorptiometry and photon absorptiometry for bone mineral measurement of lumbar spine. Mayo Clin Proc 1988; 63:1075-1084.
35. Lindsay R, Cosman F, Zhou H, Bostrom MP, Shen VW, Cruz JD, et al. A novel Tetracycline Labelling Schedule for Longitudinal Evaluation of the Short-Term Effects of Anabolic Therapy With a Single Iliac Crest Bone Biopsy: Early Actions of Teriparatide. J Bone Miner Res 2006;21(3):366-373.
36. Odgaard A, Gundersen HJG. Quantification of connectivity in cancellous bone, with special emphasis on 3-D reconstruction. Bone 1993;14:173-182.
37. Odgaard A. Three-Dimensional methods for Quantification of Cancellous Bone Architecture. Bone 1997;20,(4) 315-328.
38. Seeman E. Bone quality. Osteoporos Int 2003;14(Suppl 5):S3-S7.
39. Seeman E. Osteocytes-martyrs for integrity of bone strength. Osteoporos Int 2006; 17:1443-1448.
40. Seeman E. The periosteum-a surface for all seasons. Osteoporos Int 2007;8:123-128.
41. Jee WSS, Tian XY, Setterberg RB. Cancellous bone minimodeling-based formation: A Frost, Takahashi Legacy. J Musculoskelet Neuronal Interact 2007;7(3):232-239.
42. Kristina Åkesson K. New approaches to pharmacological treatment of osteoporosis. Bull World Health Organ 2003;81:657-664.
43. Riggs BL, Parfitt AM. Perspective; Drugs Used to Treat Osteoporosis: The Critical Need for a Uniform Nomenclature Based on Their Action on Bone Remodeling. J Bone Miner Res 2005;20:177-184.
44. Kleerekoper M. Osteoporosis prevention and therapy. preserving and building strength through bone quality Osteoporos Int (2006);17:1707-1715.
45. Gillespie LD, Gillespie WJ, Robertson MC, Lamb SE, Cumming RG, Rowe BH. Interventions for preventing falls in elderly people. Cochrane Database of Systematic Reviews. Accession Number:00075320-100000000-00635; 4, 2007.
46. Jackson RD, LaCroix A, Gass M, Wallace RB, et.al. Calcium plus Vitamin D Supplementation and the Risk of Fracture. NEJM 2006;344(7):667-683.
47. Avenell A, Handoll HHG. Nutritional supplementation for hip fracture aftercare in older people. Cochrane Database of Systematic Reviews. Accession Number:00075320-100000000-01344; 4, 2007
48. Milne AC, Potter J, Avenell A. Protein and energy supplementation in elderly people at risk from malnutrition. Cochrane Database of Systematic Reviews. Accession Number:00075320-100000000-02297;4, 2007.
49. Avenell A, Gillespie WJ, Gillespie LD, O'Connell DL. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database of Systematic Reviews. Accession Number 00075320-100000000-00018; 4, 2007.
50. Meunier PJ, Boivin G. Bone mineral density reflects bone mass but also the degree of mineralisation of bone: therapeutic implications. Bone 1997;21:373-377.
51. Boivin G, Meunier PJ. The degree of mineralisation of bone tissue measured by computerized quantitative contact microradiography. Calcif Tissue Int 2002;70:503-511.
52. Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer JT, et al. Prevalence of Vitamin D Inadequacy among Postmenopausal North American Women Receiving Osteoporosis Therapy. J Clin Endocrinol Metab 2005;90: 3215-3224.
53. Degens H. Age-related skeletal muscle dysfunction: causes and mechanisms. J Musculo skelet Neuronal Interact 2007;7(3):246-252.
54. Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005; 20:1244-1253.
55. Parfitt AM. The coupling of bone formation to bone resorption: a critical analysis of the concept and its relevance to the pathogenesis of osteoporosis. Metab Bone Dis Relat Res 1982; 4:1-6.
56. Feldstein AC, Vollmer WM, Smith DH, Petrick A, Schneider J, Glauber H, et al. An outreach program improved osteoporosis management after a fracture. J Bone Min Res 2007; 22: S508.
57. Walsh MC, Hunter GR, Livingstone MB. Sarcopenia in premenopausal and postmenopausal women with osteopenia, osteoporosis and normal bone mineral density. Osteoporos Int 2006; 17: 61-67.
58. U.S. Preventive Services Task Force. Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Women: Recommendations from the U.S. Preventive Services Task Force. Ann Intern Med 2005;142:855-860.
59. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene:results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE). JAMA 1999; 282: 637-645.
60. National Institute for Clinical Excellence (NICE) Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulato rs (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. London; NICE Technology Appraisal 87, 2005.
61. Liberman UA. Hip and non-spine fracture risk reductions differ among antiresortive agents: evidence from randomized controlled trial. Int J Clin Pract 2006;60(11):1394-1400.
62. Bianchi G, Sambrook P. Oral nitrogen-containing bisphosphonates: a systematic review of randomized clinical trials and vertebral fractures. Curr Med Res Opin 2008; Aug 8.
63. Papapoulos SE, Quandt SA, Liberman UA. Meta-analysis if the eficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 2005; 16: 468-474.
64. Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow up. J Clin Endocrinol Metab 1998;83:396-402.
65. Reginster JY, Minne HW, Sorensen OH. Randomizad trial of the effects of risendonate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91.
66. McClung MR, Geusens P, Millar PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Goup. N Engl J Med 2001;344:333-340.
67. Cranney A, Adachi JD, Guyatt G, Papaioannou A, Robinson VA, Shea BJ, et al. Risedronate for the prevention and treatment of postmenopausal osteoporosis. Cochrane Database of Systematic Reviews. Accession Number:00075320-100000000-03532;4, 2007
68. Schreck B, Serota A, Helfet D, Peterson MGE, Sinha N, Lane JM. Vitamin D Deficiency: a common occurrence in both high and low energy fractures. J Bone Min Res 2007;22: S481.
69. Chesnut CH III, Skag A, Christiansen C. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19:1241-1249.
70. Register JY, Adami S, et.al. Efficacy and tolerability of one-monthy oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Annals of the Rheumatic Diseases 2006; 65:654-661.
71. United States Food and Drug Administration, Center for Drug Evaluation and Research. Application Number 21-455. Bonviva Medical Review. (Accessed May 27, 2006). Available at: http://www.fda.gov/cder/foi/nda/2003/21-455_Bonviva_medr:P1.pdf
72. Lyles K, Colon-Emeric C, Magaziner J, Adachi J, Pieper C, HyldstrupL, et al. Efficacy and safety of zolendronic acid 5mg. in preventing fractures in men and women with prevalent hip fracture: the HORIZON recurrent fracture trial. J Bone and Min Res 2007;22:S16.
73. Bolland MJ, Grey A, Horne A, Briggs S, Thomas M, Ellis-Pegler R, et al. The effects of intravenous zolendronate on bone turnover and bone density persist for at least 24 months. J Bone Min res 2007:22:S 325.
74. Hagenau T, Vest R, Gissel T, Poulsen CS, Erlandsen M, Mosekilde L, et al. Global Vitamin levels in realtion to age, gender, etnicity and latitude: an ecologic metaregression analysis. J Bone Min Res 2007;22:S401.
75. Clark P, Carlos F, Barrera C, Guzman J, Maetzel A, Lavielle P, et al. Direct costs of osteoporosis and hip fracture: an analysis for the Mexican healthcare system. Osteoporos Int 2008;19(3):269-276.
76. Aurbach GD. Isolation of parathyroid hormone after extraction with phenol. J Biol Chem 1959; 234:3179.
77. Alexandre C, Chappard D, Caulin F, Bertrand A, Palle S, Riffat G. Effects of a one-year administration of phosphate and intermittent calcitonin on bone-forming and bone-resorbing cells in involutional osteoporosis: a histomorphometric study. Calcif Tissue Int 1988;42:345-350.
78. Neer RM, Rnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441.
79. Black DM, Greenspan SL, Enrud KE, Palermo L, McGowan JA, Lang TF, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-1215.
80. Marie P. Mechanisms of action and therapeutic potential of strontium in bone- Calcif. Tissue Int 2001;69(3):121-129.
81. Marie PJ. Optimizing bone metabolism in osteoporosis: insight into the pharmacologic profile of estrontium renalate. Osteoporosis Int 2003;14:S9-S12.
82. Meunier PJ. The effects of Strontium Ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350(5):459-468.
83. O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database of Systematic Reviews. Accession Number: 00075320-100000000-04300; 4, 2007.
84. Matkovic V, Kostial K, Simonovic I. Bone status and fracture rates in two regions of Yugoslavia. Am J Clin Nutr 1979;32:540-549.
85. Miller P, Bolognese M, Lewiecky EM, McClung M, Ding B, Liu Y, et al. Effect of denosumab on bone mineral density and bone turnover markers: 48-month results. J Bone Min Res 2007:22: S58.
86. Westover AJ, Chagnovich D, Long MW. Dual action cathepsin K inhibitors: modulation of human osteoclast function. J Bone Min Res 2007;22:S204.
87. KR62980 a novel compound, enhances bone formation through promoting osteoblastogenesis and inhibiting osteoclastogenesis. J Bone Min Res 2007;22;S204.